Wall Street Zen Downgrades NextCure (NASDAQ:NXTC) to Sell

NextCure (NASDAQ:NXTC) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other research firms have also recently issued reports on NXTC. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of NextCure in a report on Wednesday. Weiss Ratings cut shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Finally, Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $19.00.

NextCure Trading Down 2.9%

NASDAQ NXTC opened at $5.99 on Friday. NextCure has a 1-year low of $1.55 and a 1-year high of $15.74. The company has a 50 day moving average of $4.43 and a 200-day moving average of $9.30. The firm has a market cap of $21.62 million, a price-to-earnings ratio of -0.35 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. On average, analysts forecast that NextCure will post -7.89 earnings per share for the current year.

Institutional Trading of NextCure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in NextCure during the 4th quarter valued at about $160,000. Millennium Management LLC bought a new stake in shares of NextCure during the fourth quarter worth approximately $185,000. Geode Capital Management LLC lifted its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after buying an additional 3,636 shares during the period. Cable Car Capital LP boosted its stake in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.